JLL vs TERN · P/E 23, rev $23.43B vs $6.12B cap
Jones Lang LaSalle Incorporated (JLL) versus Terns Pharmaceuticals Inc (TERN) — a side-by-side from cached financials, not a winner call.
Jones Lang LaSalle Incorporated (JLL) is a real estate services company listed on US.
Terns Pharmaceuticals Inc (TERN) is a biotechnology company listed on NASDAQ.
Latest reported JLL revenue for 2024-12-31 was $23.43B. Net income was $546.8M. Revenue was up 12.9% from 2023-12-31 to 2024-12-31. JLL currently screens at market cap $12.12B and trailing P/E 23.0.
Latest reported TERN revenue for 2022-12-31 was $0. Net income was -$60.3M. TERN currently screens at market cap $6.12B.
JLL currently screens at market cap $12.12B and trailing P/E 23.0. TERN currently screens at market cap $6.12B.
Not investment advice. Open the JLL and TERN stock pages for the full models.
Not investment advice.